80259-07-0

Upstream product

• 618-61-1 3-methyl-5-nitro-aniline 
• 124-63-0 methanesulfonyl chloride 
• 75-09-2 dichloromethane 
• 603-83-8 3-nitro-o-tolylamine 

Downstream Products

• 52980-19-5 N-(3-amino-2-methyl-phenyl)-methanesulfonamide 
• 709016-00-2 N-[3-(2-bromo-benzylamino)-2-methyl-phenyl]-methanesulfonamide 
• 448952-94-1 N-{3-[benzyl(2-bromobenzyl)amino]-2-methylphenyl}methanesulfonamide 
• 80266-40-6 N-[3-(Acridin-9-ylamino)-2-methyl-phenyl]-methanesulfonamide; hydrochloride 
• 1610886-19-5 N-(3-((4-(3,4-dimethyl-2-oxo-2,3-dihydrothiazol-5-yl)pyrimidin-2-yl)amino)-2-methylphenyl)methanesulfonamide 

Relevant academic research and scientific papers

Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: Synthesis, SAR analysis and biological evaluation

Phosphorylation of eIF4E by human mitogen-activated protein kinase (MAPK)-interacting kinases (Mnks) is crucial for human tumourigenesis and development. Targeting Mnks may provide a novel anticancer therapeutic strategy. However, the lack of selective Mnk inhibitors has so far hampered pharmacological target validation and clinical drug development. Herein, we report, for the first time, the discovery of a series of 5-(2-(phenylamino) pyrimidin-4-yl)thiazole-2(3H)-one derivatives as Mnk inhibitors. Several derivatives demonstrate very potent Mnk2 inhibitory activity. The most active and selective compounds were tested against a panel of cancer cell lines, and the results confirm the cell-type-specific effect of these Mnk inhibitors. Detailed cellular mechanistic studies reveal that Mnk inhibitors are capable of reducing the expression level of anti-apoptotic protein Mcl-1, and of promoting apoptosis in MV4-11 acute myeloid leukaemia cells. Highly active Mnk2 inhibitors: Mnk-related cancer biology is an area of intensive research, but its inhibitor discovery has lagged behind due to a lack of understanding of the protein structure. Herein we report the discovery of Mnk2 inhibitors (e.g. 8 e). These potent and selective inhibitors are extremely valuable for target validation and drug discovery.

Discovery of novel nonsteroidal glucocorticoid receptor modulators

A new class of selective nonsteroidal glucocorticoid receptor modulators typified by N-{3-[benzyl-(4-chloro-2-fluoro-benzyl)-amino]-2-methyl-phenyl}- methanesulfonamide 19 has been discovered.

GLUCOCORTICOID RECEPTOR MODULATORS

Compounds of formula (I) or pharmaceutically acceptable salts thereof are novel glucocorticoid receptor modulators and are useful for treating type II diabetes in a mammal.

2-IMIDAZOLINE, 2-OXAZOLINE, 2-THIAZOLINE, AND 4-IMIDAZOLE DERIVATIVES OF METHYLPHENYL, METHOXYPHENYL, AND AMINOPHENYL ALKYLSULFONAMIDES AND UREAS AND THEIR USE

The present invention concerns novel compounds represented by the Formula: STR1 wherein: A is R 1 q (R 3 R 60 N). sub.m (Z)(NR 2) n ; m and q are each 0 or 1, with the proviso that when q is 1, m is 0 and when q is 0, m is 1; Z is C=O or SO 2 ; n is 1 with the proviso that, when Z is C=O, m is 1; X is--NH--,--CH 2--, or--OCH 2--; Y is 2-imidazoline, 2-oxazoline, 2-thiazoline, or 4-imidazole; R 1 is H, lower alkyl, or phenyl, with the proviso that, when R 1 is H, m is 1; R 2, R 3, R 60 are each independently H, lower alkyl, or phenyl; R 4, R 5, R. sup.6, and R 7 are each independently hydrogen, lower alkyl,--CF. sub.3, lower alkoxy, halogen, phenyl, lower alkeny, hydroxyl, lower alkylsulfonamido, or lower cycloalkyl, wherein R. sup.2 and R 7 optionally may be taken together to form alkylene or alkenylene of 2 to 3 atoms in an unsubstituted or optionally substituted 5-or 6-membered ring, wherein the optional substituents on the ring are halo, lower alkyl, or--CN, with the proviso that, when R 7 is hydroxyl or lower alkylsulfonamido, then X is not--NH--when Y is 2-imidazoline. The compounds include pharmaceutically acceptable salts of the above. In the above formula A may be, for example, (R 1 SO 2 NR 2--), (R. sup.3 R 60 NSO 2 NR 2--), or (R 3 R 60 NCONR 2--). The invention also includes the use of the above compounds, and compositions containing them, as alpha 1A/1L agonists in the treatment of various disease states such as urinary incontinence, nasal congestion, priapism, depression, anxiety, dementia, senility, Alzheimer's, deficiencies in attentiveness and cognition, and eating disorders such as obesity, bulimia, and anorexia.

Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists

The present invention concerns novel compounds represented by the Formula:*(formula 02)* wherein: A is R1q(R3R60N)m(Z)(NR2)n; m and q are each 0 or 1, with the proviso that when q is 1, m is 0 and when q is 0, m is 1; Z is C=O or SO 2; n is 1 with the proviso that, when Z is C=O, m is 1; X is -NH-, -CH2-, or -OCH2-; Y is 2-imidazoline, 2-oxazoline, 2-thiazoline, or 4-imidazole; R 1 is H, lower alkyl, or phenyl, with the proviso that, when R1 is H, m is 1; R2, R3, R60 are each independently H, lower alkyl, or phenyl; R4, R5, R6, and R7 are each independently hydrogen, lower alkyl, - CF 3, lower alkoxy, halogen, phenyl, lower alkeny, hydroxyl, lower alkylsulfonamido, or lower cycloalkyl, wherein R2 and R7 optionally may be taken together to form alkylene or alkenylene of 2 to 3 atoms in an unsubstituted or optionally substituted 5-or 6-membered ring, wherein the optional substituents on the ring are halo, lower alkyl, or -CN,with the proviso that, when R7 is hydroxyl or lower alkylsulfonamido, then X is not -NH- when Y is 2-imidazoline. The compounds include pharmaceutically acceptable salts of the above. In the above formula A may be, for example, (R1SO2NR2-), (R3R60NSO2NR2-), or (R3R60NCONR2-). The invention also includes the use of the above compounds, and compositions containing them, as alpha 1A/1L agonists in the treatment of various disease states such as urinary incontinence, nasal congestion, priapism, depression, anxiety, dementia, senility, Alzheimer's, deficiencies in attentiveness and cognition, and eating disorders such as obesity, bulimia, and anorexia.

Potential Antitumor Agents. 36. Quanitative Relationships between Experimental Antitumor Activity, Toxicity, and Structure for the General Class of 9-Anilinoacridine Antitumor Agents

Quantitative relationships (QSAR) have been derived between antileukemic (L1210) activity and agent physicochemical properties for 509 tumor-active members of the general class of 9-anilinoacridines.One member of this class is the clinical agent m-AMSA (NSC 249992).Agent hydrophobicity proved a significant but not a dominant influence on in vivo potency.The electronic properties of substituent groups proved important, but the most significant effects on drug potency were shown by the steric influence of groups placed at various positions on the 9-anilinoacridine skeleton.The results are entirely consistent with the physiologically important step in the action of these compounds being their binding to double-stranded DNA by intercalation of the acridine chromophore between the base pairs and positioning of the anilino group in the minor groove, as previously suggested.An equation was also derived for the acute toxicities of 643 derivatives of 9-anilinoacridine.This equation took a somewhat similar form to the one modeling antileukemia potency, emphasizing the usual fairly close relationship between potency and acute toxicity for antitumor agents in general.This study demonstrated the power of QSAR techniques to structure very large amounts of biological data and to allow the extraction of useful information from bearing on the possible site of action of the compounds concerned.